Market Overview - U.S. equities showed resilient but volatile performance in Q4, with major indexes near all-time highs while market conditions shifted significantly beneath the surface [2] - The S&P 500 Index returned 2.7% during the quarter, while the Russell Midcap Growth Index declined 3.7%, indicating increased selectivity among investors [3] Performance Analysis - The ClearBridge Growth Strategy outperformed its benchmark for the third consecutive quarter, benefiting from early-quarter momentum in AI-related sectors and strong downside protection as risk appetite moderated [4] - The Strategy delivered a strong year, outperforming its benchmark by nearly 600 basis points (gross of fees), highlighting the importance of stock selection in a market where much of the upside is already priced in [6] Sector Contributions - Positive contributions came from the consumer discretionary and materials sectors, while the consumer staples and information technology sectors detracted from performance [20] - Notable contributors included Vertex Pharmaceuticals, Broadcom, Freeport-McMoRan, and TE Connectivity, while detractors included e.l.f. Beauty and Doximity [22] Portfolio Positioning - The Strategy reallocated capital towards opportunities with more attractive risk-reward profiles, including new positions in Vistra, Alnylam Pharmaceuticals, and Hilton [14] - The portfolio is more diversified across sectors and subsectors, improving resilience while maintaining the ability to capture long-term upside [7] Outlook - The outlook remains consistent with earlier assessments, emphasizing the importance of disciplined stock selection and a balanced approach to portfolio construction amid increased volatility [17] - AI continues to represent a long-term opportunity, with a focus on maintaining exposure within the AI complex while balancing offensive and defensive characteristics in the portfolio [18]

Company Performance - Doximity (DOCS) closed at $41.36, down 5.7% from the previous trading session, underperforming the S&P 500's loss of 0.19% [1] - Over the past month, Doximity shares have decreased by 1.77%, while the Medical sector gained 0.48% and the S&P 500 increased by 2.26% [1] Upcoming Earnings - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected at $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $1.56 per share and revenue of $645.29 million for the year, indicating increases of 9.86% and 13.13% respectively compared to the previous year [3] - Changes in analyst estimates for Doximity are important as they reflect short-term business trends [3] Analyst Ratings - The Zacks Rank system rates Doximity as 2 (Buy), with a history of outperforming the market, particularly 1 stocks returning an average annual gain of 25% since 1988 [5] - The Zacks Consensus EPS estimate has increased by 0.78% in the past month [5] Valuation Metrics - Doximity has a Forward P/E ratio of 28.04, which is a discount compared to the industry average Forward P/E of 29.42 [6] - The PEG ratio for Doximity is currently 1.48, while the Medical Info Systems industry has an average PEG ratio of 2.33 [6] Industry Context - The Medical Info Systems industry is ranked 160 in the Zacks Industry Rank, placing it in the bottom 35% of over 250 industries [7] - Top-rated industries (top 50%) tend to outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - OpenAI has launched its first AI healthcare product, "ChatGPT Health," aimed at enhancing understanding and attention to personal health, following a report indicating over 230 million weekly health-related inquiries on ChatGPT [1][10] - The development of ChatGPT Health took nearly two years, guided by over 260 doctors, and is designed to complement clinical care rather than replace it [1][12] - The product integrates with various health applications, including Apple Health, and will initially be available to a limited user base before expanding to all web and iOS users [1][12] Product Features - ChatGPT Health can interpret medical documents in layman's terms and organize user data to formulate specific questions for healthcare providers [4][15] - The product emphasizes privacy and security, ensuring that all interactions and connected applications are stored separately from other chat content [4][15] - The AI medical assessment framework, HealthBench, was established based on feedback from over 60,000 interactions across 30 key areas, outperforming human doctors in response accuracy by four times [4][15] Strategic Moves - OpenAI has recruited key executives from the healthcare sector, including Nate Gross, co-founder of Doximity, to lead its healthcare strategy [5][16] - The company reports that one in four of its over 800 million users submits health-related questions weekly, with more than 40 million daily inquiries [7][18] - OpenAI collaborates with b.well, a major real-time data company, to assist users in importing health records and other medical data, amidst competition from Google, which has also partnered with b.well [8][19] Industry Positioning - OpenAI is not solely relying on a general-purpose chatbot but is building vertical models on top of its core model, which is crucial in the current competitive landscape among AI giants [8][19] - The company has launched various initiatives in the healthcare sector, including partnerships with pharmaceutical companies for drug development and regulatory discussions with the FDA [9][20] - Sam Altman, CEO of OpenAI, has expressed strong belief in the potential of AI in biotechnology, investing in AI-driven pharmaceutical companies [9][20]

Company Performance - Doximity (DOCS) closed at $43.53, down 3.22% from the previous day's closing price, underperforming the S&P 500 which gained 0.46% [1] - The stock has decreased by 9.95% over the past month, while the Medical sector gained 1.59% and the S&P 500 increased by 4.22% [1] Upcoming Financial Results - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected to be $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, representing a 9.86% increase from the prior year [3] - Revenue for the fiscal year is estimated at $645.29 million, indicating a 13.13% increase from the previous year [3] Analyst Estimates and Revisions - Recent modifications to analyst estimates for Doximity indicate short-term business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity at 3 (Hold) [6] Valuation Metrics - Doximity has a Forward P/E ratio of 28.75, which is a discount compared to the industry average Forward P/E of 46.25 [6] - The company has a PEG ratio of 1.52, significantly lower than the Medical Info Systems industry's average PEG ratio of 3.49 [7] Industry Context - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 102, placing it in the top 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Group 1: Healthpeak Properties Inc - Healthpeak Properties Inc has shown a strong performance in the healthcare real estate sector, with a focus on life science and senior housing properties [1] - The company reported a revenue increase of 5% year-over-year, reaching $500 million in the latest quarter [1] - Healthpeak's strategic acquisitions and developments in key markets have positioned it well for future growth [1] Group 2: Doximity Inc - Doximity Inc has experienced significant user growth, with a 20% increase in active users, now totaling 1.8 million [1] - The company reported a revenue of $100 million, reflecting a 15% year-over-year growth, driven by increased demand for its telehealth services [1] - Doximity's innovative platform continues to attract healthcare professionals, enhancing its market position [1]

Core Insights - Tempus AI (TEM) experienced a significant quarter with improved diagnostics volumes and pricing, alongside extended data partnerships enhancing visibility [1] - Investors are evaluating growth sustainability against GAAP losses and the timing of multi-year data deal conversions [1] Revenue Growth and Performance - In Q3 2025, revenues surged 84.7% year-over-year to $334.2 million, driven by a 117% increase in genomics to $252.9 million and a 26.1% rise in data and services to $81.3 million [2] - The company conducted 217,000 clinical tests, marking a 33% year-over-year increase, with oncology testing revenue at $139.5 million and hereditary testing at $102.6 million [2] Margin and Profitability Trends - Gross profit increased by 98% to $209.9 million due to higher volumes and improved average selling prices [3] - Adjusted EBITDA reached $1.5 million, a notable improvement from the previous year's loss, although GAAP net loss was substantial at $80.0 million [3] Pricing and Regulatory Developments - Average reimbursement improved by mid-teens percentage per test, narrowing the gap with competitors [4] - Approximately one-third of xT CDx volume is on FDA-approved pathways, with plans to migrate most by 2026, and xF submission for FDA approval expected by the end of 2025 [4] Data Monetization and Future Visibility - Data and services are showing momentum in multi-quarter bookings, which are expected to convert over time, enhancing operating leverage [5] - The company is building a backlog through Compass CRO awards and real-world data collaborations, although the conversion cycle may limit near-term revenue growth [5] Financial Position and Guidance - Tempus AI ended Q3 with $764.3 million in cash and marketable securities, providing sufficient capacity for AI compute, regulatory filings, and commercial investments [6] - For 2025, management anticipates approximately $1.265 billion in revenue and around $20 million in adjusted EBITDA, with a target for positive annual earnings per share by 2027 [6]

Group 1 - Doximity, Inc. reported a 2Q26 non-GAAP EPS of $0.45, beating estimates by approximately $0.07 [1] - Revenue for Doximity was $168.5 million, exceeding consensus expectations by $10.91 million and reflecting a year-over-year increase of 23.2% [1]

Core Insights - Doximity (DOCS) has been underperforming in the market despite its strong cash flow and niche dominance, often trading like a penny stock when market sentiment shifts [1] Company Analysis - Doximity is recognized for its robust cash generation and market position, yet its stock price does not reflect its underlying economic strength [1] - The company operates in a sector where market perceptions can significantly impact stock performance, leading to volatility [1] Investment Perspective - The investment strategy focuses on identifying mispriced opportunities where market valuations diverge from a company's fundamental performance [2] - There is an emphasis on cash flow durability, balance sheet strength, and understanding the risks associated with capital structures [2] - The approach seeks to capitalize on cyclical industries and under-followed mid-cap companies, where market expectations may not align with reality [2] - Asymmetric setups are targeted, particularly in cases where companies have already faced market punishment while their fundamentals are stabilizing or improving [2]

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1] Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe [2] - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A being the highest score [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score evaluates a company's future prospects by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends by assessing factors like one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with attractive value, strong growth forecasts, and promising momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to ensure potential upside [10] Earnings Estimate Revisions - The direction of earnings estimate revisions is crucial when selecting stocks, as stocks with lower ranks (e.g., 4 or 5) may still decline despite having high Style Scores [11] Company Spotlight: Doximity - Doximity is a leading professional medical network in the U.S., reaching over 80% of physicians and 60% of advanced practice providers [12] - Doximity holds a 3 (Hold) Zacks Rank and a VGM Score of B, indicating potential for growth [12] - The company has a Growth Style Score of A, with a forecasted year-over-year earnings growth of 10.6% for the current fiscal year [13] - Recent analyst revisions have increased the earnings estimate for fiscal 2026, with the Zacks Consensus Estimate rising to $1.57 per share [13] - Doximity has an average earnings surprise of +27.9%, making it a strong candidate for growth investors [13][14]

Core Insights - The article emphasizes the importance of utilizing Zacks Premium for investors to enhance their stock market strategies and confidence in investing [1][2] Zacks Style Scores - Zacks Style Scores provide a unique rating system for stocks based on value, growth, and momentum characteristics, aiding investors in selecting securities with high potential for market outperformance over the next 30 days [3][4] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Score identifies attractive and discounted stocks using various financial ratios such as P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [5] Momentum Score - The Momentum Score helps investors capitalize on price trends by evaluating short-term price changes and earnings estimate shifts [6] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with the best value, growth potential, and momentum, serving as a strong indicator alongside the Zacks Rank [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8][10] - There are typically over 800 top-rated stocks available, making it essential to utilize Style Scores for effective selection [9] Stock Highlight: Doximity (DOCS) - Doximity is the leading professional medical network in the U.S., reaching over 80% of physicians and 60% of advanced practice providers, offering a HIPAA-compliant platform for various digital solutions [12] - Doximity holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of B, indicating strong potential for growth [12][13] - The company is projected to achieve year-over-year earnings growth of 7.8% for the current fiscal year, with recent upward revisions in earnings estimates [13]